Technology: CAR-T therapy, Cell-based gene therapy, End-to-end Drug Development
Industry: End-to-end Drug Development, Public
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2015-01-01
Employees Number: 101-250
Funding Status: M&A
Investors Number: 11
Total Funding: 161000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2017-12-05
Last Funding Type: Series B

Visit Website
Register and Claim Ownership